inflammation

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A newly acquired Novartis drug successfully lowered signs of inflammation in a midstage study, as experts wait to hear how the company plans to advance the drug as a potential cardiovascular treatment.  In […]